Andrew R. Haas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andrew R. Haas has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Daniel H. Sterman
NYU Langone Health 1 Division of Pulmonary and Critical Care Medicine, New York UniversityGrossman School of Medicine New York, New York
6 shared publications - Anthony R. Lanfranco
Division of Pulmonary, Allergy and Critical Care Medicine
2 shared publications Colin T. Gillespie
Pulmonary, Allergy and Critical Care Division, University of Pennsylvania Medical Center, Philadelphia, PA
2 shared publications- David M. DiBardino
Section of Interventional Pulmonology, Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia, PA
2 shared publications - Jamie L. Bessich
Division of Pulmonary, Critical Care and Sleep Medicine, New York University, New York, NY, USA
2 shared publications Jonathan Puchalski
Division of Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, CT
2 shared publications
Latest Publications
- 1 July 2017
- Vol. 14 (7)
Reply: A Cautionary Tale and Opportunities for Improvement in Transbronchial Cryobiopsy.
- 1 July 2017
- Vol. 14 (7)
Reply: A Cautionary Tale and Opportunities for Improvement in Transbronchial Cryobiopsy.
- 1 July 2017
- Vol. 14 (7)
Reply: Careful Planning Reduces Cryobiopsy Complications.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3081
Phase I study of gene mediated cytotoxic immunotherapy (GMCI) for patients with malignant pleural effusion (MPE).
3081 Background: GMCI is a tumor-specific immune-stimulator through local delivery of aglatimagene besadenovec, an adenovirus-based vector expressing the HSV-1 thymidine kinase gene (AdV-tk) followed by administration of an anti-herpetic prodrug. Immunogenic tumor cell death and superantigen-mediated T cell stimulation leads to CD8 T cell dependent protection against tumor challenge in preclinical models. Methods: The primary end-point of this dose escalation trialwas safety of GMCI followed by standard chemotherapy. Eligibility included patients (pts) with MPE with a clinical indication for placement of pleural catheter, age > 18 yrs, ECOG PS 0-1, FEV1 > 40% predicted and adequate end organ function. Intra-pleural (IP) AdV-tk was administered at doses of 1x 1012 vector particles (vp) (Cohort 1); 1x1013 vp (Cohort 2); and 1x1013 vp plus celecoxib (Cohort 3). Three pts were treated per cohort with 10 pts in the expansion phase. Valacyclovir (2 gm PO TID x 14 days) started the day after AdV-tk followed by chemotherapy. Secondary end-points included response rate, progression free survival, overall survival and immune response. Results: From 2013 to 2015, 19 pts were enrolled and completed therapy: median age 68 years (range 42-89), 14 malignant mesothelioma (MM) (9 epithelioid, 3 sarcomatoid, 2 biphasic), 4 non-small cell lung cancer (NSCLC) and 1 breast cancer. All 3 pts in cohort 2 experienced transient cytokine release syndrome (CRS), with fever, nausea and chills (grade 2) plus hypotension in 1 pt. Addition of prophylactic celecoxib in cohort 3 (n = 13) reduced the incidence and severity of CRS (23% grade 1, 23% grade 2). Response according to RECIST was evaluable for 16 pts, one pt with MM had a PR, 12 SD, and 3 PD. Eight pts are alive and in active follow up (5-17 months), 3 pts with NSCLC are on active treatment with PFS 6.8-10.6 months and OS 9.4-11.8 months. Immune studies on pt samples are ongoing, and will be presented at the meeting. Conclusions: GMCI can be safely administered at high-doses IP followed by systemic chemotherapy. CRS symptoms due to immune stimulation after IP AdV-tk can be diminished with celecoxib prophylaxis. Phase II studies are warranted to further determine efficacy. Clinical trial information: NCT01997190.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3081
Phase I study of gene mediated cytotoxic immunotherapy (GMCI) for patients with malignant pleural effusion (MPE).
3081 Background: GMCI is a tumor-specific immune-stimulator through local delivery of aglatimagene besadenovec, an adenovirus-based vector expressing the HSV-1 thymidine kinase gene (AdV-tk) followed by administration of an anti-herpetic prodrug. Immunogenic tumor cell death and superantigen-mediated T cell stimulation leads to CD8 T cell dependent protection against tumor challenge in preclinical models. Methods: The primary end-point of this dose escalation trialwas safety of GMCI followed by standard chemotherapy. Eligibility included patients (pts) with MPE with a clinical indication for placement of pleural catheter, age > 18 yrs, ECOG PS 0-1, FEV1 > 40% predicted and adequate end organ function. Intra-pleural (IP) AdV-tk was administered at doses of 1x 1012 vector particles (vp) (Cohort 1); 1x1013 vp (Cohort 2); and 1x1013 vp plus celecoxib (Cohort 3). Three pts were treated per cohort with 10 pts in the expansion phase. Valacyclovir (2 gm PO TID x 14 days) started the day after AdV-tk followed by chemotherapy. Secondary end-points included response rate, progression free survival, overall survival and immune response. Results: From 2013 to 2015, 19 pts were enrolled and completed therapy: median age 68 years (range 42-89), 14 malignant mesothelioma (MM) (9 epithelioid, 3 sarcomatoid, 2 biphasic), 4 non-small cell lung cancer (NSCLC) and 1 breast cancer. All 3 pts in cohort 2 experienced transient cytokine release syndrome (CRS), with fever, nausea and chills (grade 2) plus hypotension in 1 pt. Addition of prophylactic celecoxib in cohort 3 (n = 13) reduced the incidence and severity of CRS (23% grade 1, 23% grade 2). Response according to RECIST was evaluable for 16 pts, one pt with MM had a PR, 12 SD, and 3 PD. Eight pts are alive and in active follow up (5-17 months), 3 pts with NSCLC are on active treatment with PFS 6.8-10.6 months and OS 9.4-11.8 months. Immune studies on pt samples are ongoing, and will be presented at the meeting. Conclusions: GMCI can be safely administered at high-doses IP followed by systemic chemotherapy. CRS symptoms due to immune stimulation after IP AdV-tk can be diminished with celecoxib prophylaxis. Phase II studies are warranted to further determine efficacy. Clinical trial information: NCT01997190.
- 1 April 2012
- Published by Wolters Kluwer Health in Journal of Bronchology & Interventional Pulmonology
- Vol. 19 (2) , 109-114
Secondary Carina Y-Stent Placement for Post–Lung-Transplant Bronchial Stenosis
Background: Post–lung-transplant bronchial stenosis (TBS) may cause significant morbidity and mortality. Although often transiently relieved by balloon bronchoplasty, stents may be required for long-term airway patency. We report a series of lung transplant patients in whom a silicone Y-stent was placed at the secondary carina for long-standing relief of post–transplant-airway stenosis. Methods: Six lung transplant patients received 10 silicone Y-stents in the secondary carina over the past 18 months for post–transplant-bronchial stenosis. All patients failed other interventional therapeutic procedures including balloon bronchoplasty and/or conventional stenting before secondary carina Y-stent placement. Patient data include 12 months’ follow-up after Y-stent insertion. The number of procedures and the interval between procedures was examined before and after secondary carina silicone Y-stent placement. Results: There was a significantly prolonged therapeutic effect accomplished in these patients after secondary carina Y-stent placement with the exception of 1 patient. When stents were tolerated by the patient, the mean number of procedures before secondary carina Y-stent insertion was 15.6, but only 4.8 after Y-stent insertion. The number of days between procedures was 24.5 days before the Y-stent insertion and 85.8 days after the Y-stent insertion. There were no complications in any patient during secondary carina Y-stent insertion. Conclusions: Secondary carina silicone Y-stent placement in TBS decreased the number of therapeutic procedures and provided longer-lasting results in most posttransplant patients who required multiple prior procedures for TBS.
- 1 April 2012
- Published by Wolters Kluwer Health in Journal of Bronchology & Interventional Pulmonology
- Vol. 19 (2) , 109-114
Secondary Carina Y-Stent Placement for Post–Lung-Transplant Bronchial Stenosis
Background: Post–lung-transplant bronchial stenosis (TBS) may cause significant morbidity and mortality. Although often transiently relieved by balloon bronchoplasty, stents may be required for long-term airway patency. We report a series of lung transplant patients in whom a silicone Y-stent was placed at the secondary carina for long-standing relief of post–transplant-airway stenosis. Methods: Six lung transplant patients received 10 silicone Y-stents in the secondary carina over the past 18 months for post–transplant-bronchial stenosis. All patients failed other interventional therapeutic procedures including balloon bronchoplasty and/or conventional stenting before secondary carina Y-stent placement. Patient data include 12 months’ follow-up after Y-stent insertion. The number of procedures and the interval between procedures was examined before and after secondary carina silicone Y-stent placement. Results: There was a significantly prolonged therapeutic effect accomplished in these patients after secondary carina Y-stent placement with the exception of 1 patient. When stents were tolerated by the patient, the mean number of procedures before secondary carina Y-stent insertion was 15.6, but only 4.8 after Y-stent insertion. The number of days between procedures was 24.5 days before the Y-stent insertion and 85.8 days after the Y-stent insertion. There were no complications in any patient during secondary carina Y-stent insertion. Conclusions: Secondary carina silicone Y-stent placement in TBS decreased the number of therapeutic procedures and provided longer-lasting results in most posttransplant patients who required multiple prior procedures for TBS.
- 1 September 2010
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 182 (5) , 589-597
Advances in Diagnostic Bronchoscopy
Diagnostic bronchoscopy has undergone two major paradigm shifts in the last 40 years. First, the advent of flexible bronchoscopy gave chest physicians improved access to the tracheobronchial tree with a rapid learning curve and greater patient comfort compared with rigid bronchoscopy. The second paradigm shift has evolved over the last 5 years with the proliferation of new technologies that have significantly enhanced the diagnostic capabilities of flexible bronchoscopy compared with traditional methods. At the forefront of these new technologies is endobronchial ultrasound. In its various forms, endobronchial ultrasound has improved diagnostic yield for pulmonary masses, nodules, intrathoracic adenopathy, and disease extent, thereby reducing the need for more invasive surgical interventions. Various navigational bronchoscopy systems have become available to increase flexible bronchoscope access to small peripheral pulmonary lesions. Furthermore, various modalities of airway assessment, including optical microscopic imaging technologies, may play significant roles in the diagnosis of a variety of pulmonary diseases in the future. Finally, the combination of new diagnostic bronchoscopy technologies and novel approaches in molecular analysis and biomarker assessment hold promise for enhanced diagnosis and personalized management of many pulmonary disorders. In this review, we provide a contemporary review of diagnostic bronchoscopy developments over the past decade.
- 1 September 2010
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 182 (5) , 589-597
Advances in Diagnostic Bronchoscopy
Diagnostic bronchoscopy has undergone two major paradigm shifts in the last 40 years. First, the advent of flexible bronchoscopy gave chest physicians improved access to the tracheobronchial tree with a rapid learning curve and greater patient comfort compared with rigid bronchoscopy. The second paradigm shift has evolved over the last 5 years with the proliferation of new technologies that have significantly enhanced the diagnostic capabilities of flexible bronchoscopy compared with traditional methods. At the forefront of these new technologies is endobronchial ultrasound. In its various forms, endobronchial ultrasound has improved diagnostic yield for pulmonary masses, nodules, intrathoracic adenopathy, and disease extent, thereby reducing the need for more invasive surgical interventions. Various navigational bronchoscopy systems have become available to increase flexible bronchoscope access to small peripheral pulmonary lesions. Furthermore, various modalities of airway assessment, including optical microscopic imaging technologies, may play significant roles in the diagnosis of a variety of pulmonary diseases in the future. Finally, the combination of new diagnostic bronchoscopy technologies and novel approaches in molecular analysis and biomarker assessment hold promise for enhanced diagnosis and personalized management of many pulmonary disorders. In this review, we provide a contemporary review of diagnostic bronchoscopy developments over the past decade.
- 1 November 2009
- Published by Wolters Kluwer Health in Clinical Pulmonary Medicine
- Vol. 16 (6) , 337-342
Endobronchial Ultrasound
The development of flexible bronchoscopy ushered in a new era of less invasive pulmonary evaluation, diagnostic procedures, and treatment. Recent technologic advances have allowed the development of an array of adjunctive ultrasound equipment that can be used during bronchoscopy for a variety of applications. This review article will discuss basic ultrasound principles, the various ultrasound tools now available for bronchoscopic utilization, and how ultrasound has expanded the role bronchoscopy can play in many aspects of thoracic medicine.
- 1 November 2009
- Published by Wolters Kluwer Health in Clinical Pulmonary Medicine
- Vol. 16 (6) , 337-342
Endobronchial Ultrasound
The development of flexible bronchoscopy ushered in a new era of less invasive pulmonary evaluation, diagnostic procedures, and treatment. Recent technologic advances have allowed the development of an array of adjunctive ultrasound equipment that can be used during bronchoscopy for a variety of applications. This review article will discuss basic ultrasound principles, the various ultrasound tools now available for bronchoscopic utilization, and how ultrasound has expanded the role bronchoscopy can play in many aspects of thoracic medicine.
- 1 April 2009
- Published by Wolters Kluwer Health in Journal of Bronchology & Interventional Pulmonology
- Vol. 16 (2) , 105-107
Endotracheal Spindle Cell Lipoma Presenting as a Chronic Cough
An elderly gentleman with a chronic cough was found to have a large midtracheal lesion on computed tomography scan. Endotracheal extirpation with an electrocautery snare successfully removed the lesion. Histologic and immunohistochemical analyses revealed the lesion to be a spindle cell lipoma. We provide herein the case presentation and management, the differential diagnosis, and an overview of spindle cell lipoma.
- 1 April 2009
- Published by Wolters Kluwer Health in Journal of Bronchology & Interventional Pulmonology
- Vol. 16 (2) , 105-107
Endotracheal Spindle Cell Lipoma Presenting as a Chronic Cough
An elderly gentleman with a chronic cough was found to have a large midtracheal lesion on computed tomography scan. Endotracheal extirpation with an electrocautery snare successfully removed the lesion. Histologic and immunohistochemical analyses revealed the lesion to be a spindle cell lipoma. We provide herein the case presentation and management, the differential diagnosis, and an overview of spindle cell lipoma.
- Open Access
- 31 March 2009
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 33 (4) , 935-938
Infectious complications from full extension endobronchial ultrasound transbronchial needle aspiration
The development of a convex probe endobronchial ultrasound (CP-EBUS) videobronchoscope to allow real-time transbronchial needle aspiration (TBNA) has been a significant advance in minimally invasive lung cancer staging and diagnosis. Several recent studies have demonstrated CP-EBUS-TBNA to have recovery rivalling that of the current gold standard, cervical mediastinoscopy. These same studies have indicated that the safety of this procedure has no reported complications.The present case study presents two infectious complications from full extension endobronchial ultrasound transbronchial needle aspiration and discusses possible aetiologies of these infections, as well as implications for future application of this technology.
- 31 March 2009
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 33 (4) , 935-938
Open AccessInfectious complications from full extension endobronchial ultrasound transbronchial needle aspiration
The development of a convex probe endobronchial ultrasound (CP-EBUS) videobronchoscope to allow real-time transbronchial needle aspiration (TBNA) has been a significant advance in minimally invasive lung cancer staging and diagnosis. Several recent studies have demonstrated CP-EBUS-TBNA to have recovery rivalling that of the current gold standard, cervical mediastinoscopy. These same studies have indicated that the safety of this procedure has no reported complications.The present case study presents two infectious complications from full extension endobronchial ultrasound transbronchial needle aspiration and discusses possible aetiologies of these infections, as well as implications for future application of this technology.